Nouscom is a private oncology company developing next generation immunotherapies. Nouscom's proprietary technology platform harnesses the full power of immune response by combining oncolytic viruses specifically targeted to a tumor with viral vectored genetic vaccines based on patient specific neo-antigens.
Co-Founder and CEO of HQ: Riccardo Cortese, PhD, MD
Co-Founder and CEO of Italy: Alfredo Nicosia, PhD
Co-Founder and CSO: Elisa Scarselli, MD
Co-Founder and CTO: Stefano Colloca, MD
Co-Founder and Head of Immunology: Antonella Folgori, PhD
Co-Founder and Senior Director of Regulatory Affairs: Cinzia Traboni, PhD
COO: Marina Udier, PhD
Please click here for Nouscom's science.